Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful vigilantly but unsuccessfully to produce a single therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past several shares. My 1st CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire job interview that I came away with a bad viewpoint of the company.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this know-how as well as connected intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) along with the first brand new drug program approval ($five million), and also royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it’s this individual therapy in addition to a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple illness types, multiple presentations and multiple publications.

Might it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the really beginning of my interest in this particular company. Judging by way of the multiples of thousands of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a classic battleground, or possibly some may say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *